These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 32035041

  • 1. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S.
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
    Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A.
    Lancet HIV; 2019 Feb; 6(2):e116-e127. PubMed ID: 30503325
    [Abstract] [Full Text] [Related]

  • 4. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN, Bansi-Matharu L, Cambiano V, Ehrenkranz P, Serenata C, Venter F, Pett S, Flexner C, Jahn A, Revill P, Garnett GP.
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [Abstract] [Full Text] [Related]

  • 5. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM, Ciaranello AL, Bekker LG, Stern ME, Myer L, Wood R, Sax PE, Abrams EJ, Freedberg KA, Walensky RP.
    Ann Intern Med; 2019 May 07; 170(9):614-625. PubMed ID: 30934067
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk-Heath M, Mthethwa S, Shai S, Mngomezulu NN, Tlhowe L, Achere-Darko J, Bedford J, Martin CE, Fairlie L, Imrie J.
    HIV Med; 2024 Jul 07; 25(7):826-839. PubMed ID: 38520085
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, Jackson JB.
    Lancet; 1999 Sep 04; 354(9181):803-9. PubMed ID: 10485721
    [Abstract] [Full Text] [Related]

  • 11. Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.
    Nightingale S, Dreyer AJ, Thomas KGF, van Zyl G, Decloedt E, Naude PJW, Orrell C, Sinxadi P, Winston A, Khoo S, Joska JA.
    Lancet HIV; 2024 Oct 04; 11(10):e680-e689. PubMed ID: 39284338
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol.
    Semengue ENJ, Santoro MM, Ndze VN, Dambaya B, Takou D, Teto G, Nka AD, Fabeni L, Wiyeh A, Ceccherini-Silberstein F, Colizzi V, Perno CF, Fokam J.
    Syst Rev; 2020 Apr 25; 9(1):93. PubMed ID: 32334643
    [Abstract] [Full Text] [Related]

  • 14. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA, Crane HM, Nance RM, Whitney BM, Harding BN, Mayer KH, Moore RD, Eron JJ, Geng E, Mathews WC, Rodriguez B, Willig AL, Burkholder GA, Lindström S, Wood BR, Collier AC, Vannappagari V, Henegar C, Van Wyk J, Curtis L, Saag MS, Kitahata MM, Delaney JAC.
    J Acquir Immune Defic Syndr; 2021 Mar 01; 86(3):339-343. PubMed ID: 33148997
    [Abstract] [Full Text] [Related]

  • 15. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
    Ochanda PN, Lamorde M, Kintu K, Wang D, Chen T, Malaba T, Myer L, Waitt C, Reynolds H, Khoo S.
    AIDS Res Ther; 2022 Jun 07; 19(1):24. PubMed ID: 35672853
    [Abstract] [Full Text] [Related]

  • 16. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study.
    Gedefaw A, Tadesse BT, Berhan Y, Makonnen E, Vella S, Aklillu E.
    BMC Infect Dis; 2024 Sep 02; 24(1):901. PubMed ID: 39223552
    [Abstract] [Full Text] [Related]

  • 17. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
    Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver D, Kripke K, Revill P, Boily MC, Meyer-Rath G, Taramusi I, Lundgren JD, van Oosterhout JJ, Kuritzkes D, Schaefer R, Siedner MJ, Schapiro J, Delany-Moretlwe S, Landovitz RJ, Flexner C, Jordan M, Venter F, Radebe M, Ripin D, Jenkins S, Resar D, Amole C, Shahmanesh M, Gupta RK, Raizes E, Johnson C, Inzaule S, Shafer R, Warren M, Stansfield S, Paredes R, Phillips AN, HIV Modelling Consortium.
    Lancet HIV; 2023 Apr 02; 10(4):e254-e265. PubMed ID: 36642087
    [Abstract] [Full Text] [Related]

  • 18. Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study.
    Facha W, Tadesse T, Wolka E, Astatkie A.
    Front Public Health; 2024 Apr 02; 12():1385441. PubMed ID: 39015389
    [Abstract] [Full Text] [Related]

  • 19. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, Kaboggoza J, Sihlangu M, Coombs JA, Malaba T, Byamugisha J, Amara A, Gini J, Else L, Heiburg C, Hodel EM, Reynolds H, Mehta U, Byakika-Kibwika P, Hill A, Myer L, Lamorde M, Khoo S.
    PLoS Med; 2019 Sep 02; 16(9):e1002895. PubMed ID: 31539371
    [Abstract] [Full Text] [Related]

  • 20. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC, Morrison RL, Shapiro DE, Chakhtoura N, Gouvèa MIS, de Lourdes B Teixeira M, Fuller TL, Mmbaga BT, Ngocho JS, Njau BN, Violari A, Mathiba R, Essack Z, Pilotto JHS, Moreira LF, Rolon MJ, Cahn P, Prommas S, Cressey TR, Chokephaibulkit K, Werarak P, Laimon L, Hennessy R, Frenkel LM, Anthony P, Best BM, Siberry GK, Mirochnick M.
    Lancet HIV; 2020 May 02; 7(5):e322-e331. PubMed ID: 32386720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.